IL273203A - Treatment of abnormal accumulation of fat in internal organs using soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides - Google Patents

Treatment of abnormal accumulation of fat in internal organs using soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides

Info

Publication number
IL273203A
IL273203A IL273203A IL27320320A IL273203A IL 273203 A IL273203 A IL 273203A IL 273203 A IL273203 A IL 273203A IL 27320320 A IL27320320 A IL 27320320A IL 273203 A IL273203 A IL 273203A
Authority
IL
Israel
Prior art keywords
sfgfr3
polypeptides
treatment
growth factor
factor receptor
Prior art date
Application number
IL273203A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pfizer
Inst Nat Sante Rech Med
Univ Cote D'azur
Centre National Recherche Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Inst Nat Sante Rech Med, Univ Cote D'azur, Centre National Recherche Scient filed Critical Pfizer
Publication of IL273203A publication Critical patent/IL273203A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL273203A 2017-09-20 2020-03-10 Treatment of abnormal accumulation of fat in internal organs using soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides IL273203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561140P 2017-09-20 2017-09-20
PCT/EP2018/075471 WO2019057820A1 (en) 2017-09-20 2018-09-20 ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

Publications (1)

Publication Number Publication Date
IL273203A true IL273203A (en) 2020-04-30

Family

ID=63878625

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273203A IL273203A (en) 2017-09-20 2020-03-10 Treatment of abnormal accumulation of fat in internal organs using soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides

Country Status (12)

Country Link
US (1) US20200297799A1 (enExample)
EP (1) EP3684394A1 (enExample)
JP (1) JP7335247B2 (enExample)
KR (1) KR20200103621A (enExample)
CN (1) CN111836634A (enExample)
AU (1) AU2018335837A1 (enExample)
BR (1) BR112020005459A2 (enExample)
CA (1) CA3076396A1 (enExample)
IL (1) IL273203A (enExample)
MX (1) MX2020003114A (enExample)
PH (1) PH12020550461A1 (enExample)
WO (1) WO2019057820A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
NL2020176B1 (en) * 2017-12-22 2019-07-02 Van Der Hoeven Horticultural Projects B V Greenhouse
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク sFGFR3ポリペプチドを生産するための細胞培養方法
WO2024147597A1 (ko) * 2023-01-03 2024-07-11 서울대학교산학협력단 Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
RS60593B1 (sr) * 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) * 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) * 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도

Also Published As

Publication number Publication date
EP3684394A1 (en) 2020-07-29
WO2019057820A1 (en) 2019-03-28
AU2018335837A1 (en) 2020-04-23
BR112020005459A2 (pt) 2020-09-29
JP2020534367A (ja) 2020-11-26
US20200297799A1 (en) 2020-09-24
RU2020113712A3 (enExample) 2022-01-14
JP7335247B2 (ja) 2023-08-29
MX2020003114A (es) 2020-10-20
KR20200103621A (ko) 2020-09-02
CN111836634A (zh) 2020-10-27
CA3076396A1 (en) 2019-03-28
PH12020550461A1 (en) 2021-03-22
RU2020113712A (ru) 2021-10-20

Similar Documents

Publication Publication Date Title
PT3653617T (pt) Processo de preparação de (s)-nicotina a partir de miosmina
PH12020550461A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
IL276116A (en) Encased artificial heart valve
ZA202000764B (en) Skirt assembly for implantable prosthetic valve
ZA202006610B (en) Compositions for the treatment of skin conditions
SG11202101611TA (en) Controlled-release urethane-elastomers for use in implantable products
ZA202007055B (en) Compositions for the treatment of skin conditions
IL281227A (en) Delayed delivery of angiopoietin-like polypeptides 3
IL283452B2 (en) FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
GB2576372B (en) Lower limb prosthesis
CA186914S (en) Frying pan
GB201706009D0 (en) Antisense oligonucleotides for the treatment of stargardt disease
PL3678589T3 (pl) Intraluminalny system protez naczyniowych
ZA201905891B (en) Peptides for treatment of diabetes
ZA202007812B (en) Method for preparing precursor of recombinant human insulin or analogue thereof
GB201916196D0 (en) Highly hydrophobic antifouling coatings for implantable medical devices
PL3606474T3 (pl) Panewka ceramiczna
ZA202100861B (en) Method for preparing recombinant human coagulation factor viii
IL279410A (en) Process for preparing Quinmark
PT3569198T (pt) Prótese craniana
PL3581525T3 (pl) Korytko przenośnika
PH32018000890S1 (en) Broiler pan feeder
GB2579575B (en) Skin preparation patches
JOP20190202A1 (ar) طبق علف الدواجن
HK40027652A (en) Treatment of neuroinflammatory disease